Yellow Fever Immune Response at Single Cell Resolution


The immune system is composed of diverse cell types with different functions that act together in order to defend against infection. This pilot study will test a new technology for studying these many different cell types at very large numbers at the level of individual cells. This method will then be used to identify the cell types and functions important for the immune response to the highly protective yellow fever vaccine, which will improve our understanding of effective vaccine features.

Study Start Date

August, 22 2016

Estimated Completion Date

May 2019


  • Drug: Yellow Fever Vaccine

Study ID

Rockefeller University -- BRO-0905



Trial ID


Study Type


Trial Phase


Enrollment Quota



Rockefeller University

Inclusion Criteria

  • Male or female between the ages of 18 and 59 years old
  • Volunteers who have not received a vaccination within 30 days of the YFV and do not anticipate to receive a vaccination within 30 days
  • Volunteers who are seeking the YFV for either travel reasons or occupational risk
  • Volunteers willing to undergo one screening visit, one visit to receive the YFV, and four post-vaccination visits
  • Volunteers without medical conditions who are willing to give blood once for the development of the inDrop technique

Exclusion Criteria

  • Male or females under 18 or over 59 years of age
  • Volunteers who received other vaccination less than 30 days prior to receiving the YFV
  • Volunteers with acute or febrile disease
  • Volunteers unable to return for the post vaccination follow-up visits
  • Volunteers with an allergy to eggs, chicken proteins, gelatin, or other components of the Yellow Fever vaccine
  • Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study
  • Is pregnant or lactating
  • Volunteers with a history of yellow fever vaccination and/or infection
  • Volunteers with a history of viral hepatitis and/or non-viral liver disease
  • In the opinion of the investigators, the volunteer is unlikely to comply with the study protocol
  • Immunosuppressed individuals as a result of cancer, transplantation, and or primary immunodeficiency
  • Immunosuppressed individuals as a result of medications (such as high-dose systemic corticosteroids, alkylating drugs, antimetabolites, TNF-? inhibitors (e.g., etanercept), IL-1 blocking agents (e.g., anakinra), and other monoclonal antibodies targeting immune cells (e.g.,rituximab, alemtuzumab) and/or radiation
  • Volunteers with thymus disorders (including myasthenia gravis, Di George syndrome, or thymoma) and/or history of thymectomy
  • Individuals infected with HIV




18 Years to 59 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
The Rockefeller University - New York, New York 187.1 miles Recruitment Specialist 800-782-2737 None provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.